We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarker Predicts Factor VIII Response in Hemophilia A

By LabMedica International staff writers
Posted on 10 Apr 2019
Hemophilia A is a genetic deficiency in clotting factor VIII (FVIII), which causes increased bleeding and usually affects males. More...
In the majority of cases it is inherited as an X-linked recessive trait, though there are cases, which arise from spontaneous mutations.

Trough factor (F) VIII level is a not reliable bleeding risk indicator to predict prophylaxis efficacy in severe hemophilia A (SHA), therefore, accurate biomarkers are in great demand by specialist hematologists. Thrombelastography (TEG) monitors both thrombin and clot formation addressing the global hemostatic status but its usefulness to tailor prophylaxis in hemophilia has been poorly evaluated.

Hematologists at the La Paz University Hospital (Madrid, Spain) analyzed a group of 19 adolescents (younger than 18 years) with severe hemophilia A (without signs of inhibitors) on long-term preventive treatment with FVIII. Of the 19 patients, six had at least one spontaneous bleeding event that required treatment in the two years preceding the study and were categorized as “bleeders.” The remaining patients were categorized as non-bleeders.

Whole blood was withdrawn before FVIII administration and at five time-points after infusion for the thrombelastography test to assess the therapy’s pharmacodynamics (what a medicine does to the body) and pharmacokinetics (what the body does to a medicine, referring to the movement of the therapy through the body) profiles. The team hypothesized that the outcomes of the laboratory test may help discern patients who exhibit a bleeding tendency from those who do not. Ten patients completed the five post-infusion time-points, while five patients missed one time-point, and four missed two time-points.

The investigators reported that the thrombelastography (TEG) analysis over time showed that the procoagulation activity of patients decreased with time after dosing with FVIII. The therapy’s effectiveness tended to be weaker in the group of bleeders compared to the non-bleeders, although the team saw no significant statistical difference. Moreover, the “half maximal effective concentration” of FVIII (FVIII-EC50), a parameter that describes the concentration at which a therapy induces a response halfway between no response and maximum response, assessed in the TEG test was significantly higher in bleeders, which suggests a poorer response to FVIII.

The authors concluded that overall, their findings support the FVIII-EC50 for the first time as a valuable biomarker to anticipate individual efficacy of prophylaxis in severe hemophilia A. Only the half maximal effective concentration of FVIII (FVIII-EC50) for TEG parameters R-time, K-time and α-angle correlated with the bleeding phenotype being significantly higher in bleeders suggestive of a poorer response to FVIII. The study was published on February 1, 2019, in the European Journal of Pharmaceutical Sciences.

Related Links:
La Paz University Hospital


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.